Quintiles announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program.
Quintiles announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program. Hospital Italiano is Quintiles’ first Prime Site in Latin America. A Prime Site is a large clinical institution selected by Quintiles to work together and enhance the institution’s infrastructure for conducting clinical trials. The new Prime Site at Hospital Italiano has dedicated research facilities, full-time study coordinators, a local College of American Pathologists (CAP)-accredited laboratory and full-service pharmacy. To date, Hospital Italiano has conducted more than 60 trials in 12 different therapy areas with Quintiles – comparable to other Quintiles Prime Sites, and delivered the required subjects for a variety of complex trials for the company.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.